J&J, Thermo Fisher partner on oncology diagnostic

March 13, 2020

Thermo Fisher Scientific has signed an agreement with Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to co-develop a companion diagnostic in oncology.

Thermo Fisher will collaborate with Janssen scientists to validate multiple biomarkers for use with Thermo Fisher's Oncomine Dx Target Test, which will be used to identify variant-positive patients for enrollment into clinical trials focused on non-small cell lung cancer.

The companion diagnostic is set to support clinical trial enrollment globally and additional indications in oncology may follow.

The companies are hopeful that this approach to patient stratification helps expedite drug development initiatives which ultimately are designed to promote targeted therapies.

Read the press release